276 related articles for article (PubMed ID: 28903138)
1. Improvement of Genetic Testing for Cutaneous Melanoma in Countries With Low to Moderate Incidence: The Rule of 2 vs the Rule of 3.
Delaunay J; Martin L; Bressac-de Paillerets B; Duru G; Ingster O; Thomas L
JAMA Dermatol; 2017 Nov; 153(11):1122-1129. PubMed ID: 28903138
[TBL] [Abstract][Full Text] [Related]
2. Genetic susceptibility to cutaneous melanoma in southern Switzerland: role of CDKN2A, MC1R and MITF.
Mangas C; Potrony M; Mainetti C; Bianchi E; Carrozza Merlani P; Mancarella Eberhardt A; Maspoli-Postizzi E; Marazza G; Marcollo-Pini A; Pelloni F; Sessa C; Simona B; Puig-Butillé JA; Badenas C; Puig S
Br J Dermatol; 2016 Nov; 175(5):1030-1037. PubMed ID: 27473757
[TBL] [Abstract][Full Text] [Related]
3. [Recommendations for genetic testing and management of individuals genetically at-risk of cutaneous melanoma].
Avril MF; Bahadoran P; Cabaret O; Caron O; de la Fouchardière A; Demenais F; Desjardins L; Frébourg T; Hammel P; Leccia MT; Lesueur F; Mahé E; Martin L; Maubec E; Remenieras A; Richard S; Robert C; Soufir N; Stoppa-Lyonnet D; Thomas L; Vabres P; Bressac-de Paillerets B
Ann Dermatol Venereol; 2015 Jan; 142(1):26-36. PubMed ID: 25600792
[TBL] [Abstract][Full Text] [Related]
4. Genetic counselling and high-penetrance susceptibility gene analysis reveal the novel CDKN2A p.D84V (c.251A>T) mutation in melanoma-prone families from Italy.
Borroni RG; Manganoni AM; Grassi S; Grasso M; Diegoli M; Giorgianni C; Favalli V; Pavoni L; Cespa M; Arbustini E
Melanoma Res; 2017 Apr; 27(2):97-103. PubMed ID: 28060055
[TBL] [Abstract][Full Text] [Related]
5. CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma.
Betti M; Aspesi A; Biasi A; Casalone E; Ferrante D; Ogliara P; Gironi LC; Giorgione R; Farinelli P; Grosso F; Libener R; Rosato S; Turchetti D; Maffè A; Casadio C; Ascoli V; Dianzani C; Colombo E; Piccolini E; Pavesi M; Miccoli S; Mirabelli D; Bracco C; Righi L; Boldorini R; Papotti M; Matullo G; Magnani C; Pasini B; Dianzani I
Cancer Lett; 2016 Aug; 378(2):120-30. PubMed ID: 27181379
[TBL] [Abstract][Full Text] [Related]
6. Multiple Cutaneous Melanomas and Clinically Atypical Moles in a Patient With a Novel Germline BAP1 Mutation.
Gerami P; Yélamos O; Lee CY; Obregon R; Yazdan P; Sholl LM; Guitart GE; Njauw CN; Tsao H
JAMA Dermatol; 2015 Nov; 151(11):1235-9. PubMed ID: 26154183
[TBL] [Abstract][Full Text] [Related]
7. Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup.
Bruno W; Pastorino L; Ghiorzo P; Andreotti V; Martinuzzi C; Menin C; Elefanti L; Stagni C; Vecchiato A; Rodolfo M; Maurichi A; Manoukian S; De Giorgi V; Savarese I; Gensini F; Borgognoni L; Testori A; Spadola G; Mandalà M; Imberti G; Savoia P; Astrua C; Ronco AM; Farnetti A; Tibiletti MG; Lombardo M; Palmieri G; Ayala F; Ascierto P; Ghigliotti G; Muggianu M; Spagnolo F; Picasso V; Tanda ET; Queirolo P; Bianchi-Scarrà G
J Am Acad Dermatol; 2016 Feb; 74(2):325-32. PubMed ID: 26775776
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of MITF p.E318K in Patients With Melanoma Independent of the Presence of CDKN2A Causative Mutations.
Potrony M; Puig-Butille JA; Aguilera P; Badenas C; Tell-Marti G; Carrera C; Javier Del Pozo L; Conejo-Mir J; Malvehy J; Puig S
JAMA Dermatol; 2016 Apr; 152(4):405-12. PubMed ID: 26650189
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of melanoma cases in Denmark suspected of genetic predisposition.
Wadt KA; Aoude LG; Krogh L; Sunde L; Bojesen A; Grønskov K; Wartacz N; Ek J; Tolstrup-Andersen M; Klarskov-Andersen M; Borg Å; Heegaard S; Kiilgaard JF; Hansen TV; Klein K; Jönsson G; Drzewiecki KT; Dunø M; Hayward NK; Gerdes AM
PLoS One; 2015; 10(3):e0122662. PubMed ID: 25803691
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of Germline BAP1, CDKN2A, and CDK4 Mutations in an Australian Population-Based Sample of Cutaneous Melanoma Cases.
Aoude LG; Gartside M; Johansson P; Palmer JM; Symmons J; Martin NG; Montgomery GW; Hayward NK
Twin Res Hum Genet; 2015 Apr; 18(2):126-33. PubMed ID: 25787093
[TBL] [Abstract][Full Text] [Related]
11. [Increased knowledge on familial melanoma and the underlying genetics].
Helgadottir H; Nielsen K; Höiom V
Lakartidningen; 2017 May; 114():. PubMed ID: 28485764
[TBL] [Abstract][Full Text] [Related]
12. A Single Center Retrospective Review of Patients from Central Italy Tested for Melanoma Predisposition Genes.
De Simone P; Bottillo I; Valiante M; Iorio A; De Bernardo C; Majore S; D'Angelantonio D; Valentini T; Sperduti I; Piemonte P; Eibenschutz L; Ferrari A; Carbone A; Buccini P; Paiardini A; Silipo V; Frascione P; Grammatico P
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33322357
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Risk of Hereditary Predisposition in Patients With Melanoma and/or Mesothelioma and Renal Neoplasia.
Gupta S; Erickson LA; Lohse CM; Shen W; Pitel BA; Knight SM; Halling KC; Herrera-Hernandez L; Boorjian SA; Thompson RH; Leibovich BC; Jimenez RE; Cheville JC
JAMA Netw Open; 2021 Nov; 4(11):e2132615. PubMed ID: 34767027
[TBL] [Abstract][Full Text] [Related]
14. Risks of Melanoma and Other Cancers in Melanoma-Prone Families over 4 Decades.
Tucker MA; Elder DE; Curry M; Fraser MC; Pichler V; Zametkin D; Yang XR; Goldstein AM
J Invest Dermatol; 2018 Jul; 138(7):1620-1626. PubMed ID: 29408205
[TBL] [Abstract][Full Text] [Related]
15. Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status.
Helgadottir H; Tuominen R; Olsson H; Hansson J; Höiom V
J Am Acad Dermatol; 2017 Nov; 77(5):893-901. PubMed ID: 28818438
[TBL] [Abstract][Full Text] [Related]
16. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma.
Tsao H; Zhang X; Kwitkiwski K; Finkelstein DM; Sober AJ; Haluska FG
Arch Dermatol; 2000 Sep; 136(9):1118-22. PubMed ID: 10987867
[TBL] [Abstract][Full Text] [Related]
17. CDKN2A/CDK4 Status in Greek Patients with Familial Melanoma and Association with Clinico-epidemiological Parameters.
Karagianni F; Njauw CN; Kypreou KP; Stergiopoulou A; Plaka M; Polydorou D; Chasapi V; Pappas L; Stratigos IA; Champsas G; Panagiotou P; Gogas H; Evangelou E; Tsao H; Stratigos AJ; Stefanaki I
Acta Derm Venereol; 2018 Oct; 98(9):862-866. PubMed ID: 29774366
[TBL] [Abstract][Full Text] [Related]
18. Multigene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families.
Potjer TP; Bollen S; Grimbergen AJEM; van Doorn R; Gruis NA; van Asperen CJ; Hes FJ; van der Stoep N;
Int J Cancer; 2019 May; 144(10):2453-2464. PubMed ID: 30414346
[TBL] [Abstract][Full Text] [Related]
19. [Genetic counseling and DNA testing in patients with increased risks for malignant melanoma].
Itin PH; Fistarol SK
Ther Umsch; 2003 Aug; 60(8):469-72. PubMed ID: 14502854
[TBL] [Abstract][Full Text] [Related]
20. Progress report on the major clinical advances in patient-oriented research into familial melanoma (2013-2018).
Visser M; van der Stoep N; Gruis N
Fam Cancer; 2019 Apr; 18(2):267-271. PubMed ID: 30659395
[No Abstract] [Full Text] [Related]
[Next] [New Search]
